Topics

AbCellera Biologics, Inc. Company Profile

22:06 EDT 15th September 2019 | BioPortfolio

AbCellera is a privately held company that develops next-generation monoclonal antibody therapies and provides enabling technologies to biotechnology and pharmaceutical partners. AbCellera’s lead technology is a proprietary single-cell antibody discovery and immune profiling platform that allows for high-throughput screening of natural immune repertoires to rapidly identify lead therapeutic antibody candidates against a wide range of target classes from any species, including humans.


News Articles [572 Associated News Articles listed on BioPortfolio]

AbCellera, Denali sign multi-target mAb discovery agreement in neurology

In a multi-year collaboration, AbCellera Biologics Inc. and Denali Therapeutics Inc. have agreed to discover therapeutic antibodies for up to eight neurological drug targets selected by Denali using A...

AbCellera signs multi-target mAb discovery agreement with Novartis

Under a multi-year collaboration, AbCellera Biologics Inc. will apply its microfluidic single-cell antibody discovery technology to advance programs on up to ten undisclosed therapeutic targets select...

Novartis Enters 10-Target Antibody Discovery Deal with AbCellera

VANCOUVER, British Columbia–(BUSINESS WIRE)–AbCellera, a technology leader in therapeutic antibody discovery from natural immune repertoires, today announced a multi-target and multi-year ...

AbCellera and Denali Therapeutics Expand Deal to Discover Therapeutic Antibodies for Neurological Diseases

VANCOUVER, British Columbia–(BUSINESS WIRE)–AbCellera today announced an expanded collaboration with Denali Therapeutics Inc. (NASDAQ:DNLI) to discover antibodies as therapies for neuro...

AbCellera & Novartis Announce Collaboration

AbCellera to apply technology to advance programs on up to ten targets elected by Novartis

AbCellera and Gilead Forge Infectious Disease Pact

AbCellera will use its technology to look for ultra-rare antibodies with specific properties defined by Gilead.

AbCellera and Novartis enter into multi-target partnership

Canada-based AbCellera has announced it has signed a multi-year, multi-target agreement with Novartis under which its antibody discovery technology will...Read More... The post AbCellera and Novartis ...

Gilead, AbCellera team up against infectious diseases

AbCellera will receive upfront and research payments and is eligible to receive downstream clinical and commercial milestone payments and royalties.

Drugs and Medications [3 Associated Drugs and Medications listed on BioPortfolio]

Atryn [revo bioloigics, inc.]

These highlights do not include all the information needed to use ATryn safely and effectively. See full prescribing information for ATryn. ATryn, Antithrombin (Recombinant) Lyophilized powder for rec...

Anticoagulant citrate dextrose a [citra labs]

ACD-A Anticoagulant Citrate Dextrose Solution, Solution A, U.S.P., PN 9350, 30 mL NDC 23731-6051-3

Rejuvesol [citra labs llc]

rejuvesol red blood cell processing solution

PubMed Articles [110 Associated PubMed Articles listed on BioPortfolio]

Biosimilars in India; Current Status and Future Perspectives.

Many key biologics are scheduled to lose their patent by the year 2020, which will provide the opportunity to other biopharmaceutical companies to develop the similar biologics. Biosimilar or similar ...

Cutaneous lymphomas appearing under biologics: 44 cases from the French Study Group on Cutaneous Lymphomas and French Pharmacovigilance Database.

Controversy exists regarding the risk and prognosis of lymphomas under biologics . Risk evaluation must consider the underlying medical condition -as chronic inflammatory diseases are associated with ...

Shifting paradigms revisited: biotechnology and the pharmaceutical sciences.

In 2003 Crommelin et al. published an article titled: 'Shifting paradigms: biopharmaceuticals versus low molecular weight drugs' (https://doi.org/10.1016/S0378-5173(03)00376-4). In the current comment...

The emergence of new biologics for severe asthma.

Patients with severe asthma experience severe symptoms and frequent exacerbations despite intensive treatment with inhaled and oral glucocorticoids. Biologics for severe asthma aim to reduce asthma-re...

Treatment of Psoriasis With Biologics and Apremilast in Patients With a History of Malignancy: A Retrospective Chart Review

Introduction: Biologics have transformed the management of moderate-to-severe psoriasis. The risk of developing a malignancy during treatment is an important consideration, and many studies have been ...

Clinical Trials [96 Associated Clinical Trials listed on BioPortfolio]

A Study Comparing Biologics + Methotrexate With Biologics + Tacrolimus in Patients With Rheumatoid Arthritis (RA)

The purpose of this study is to compare the efficacy of Biologics + Methotrexate with Biologics + Tacrolimus measured by the disease activity score 28 (DAS28) erythrocyte sedimentation rat...

Ustekinumab Safety and Surveillance Program Using the Ingenix NHI Database

The patients included in this observational study will be drawn from a research database containing claims and enrollment data for members of a large, geographically diverse US health plan...

Golimumab Safety and Surveillance Program Using the Ingenix NHI Database

The participants included in this observational study will be drawn from a research database containing claims and enrollment data for members of a large, geographically diverse US health ...

Tofacitinib Registry of Patients With Ulcerative Colitis in Germany

This registry on Tofacitinib and biologics (anti-integrin/anti-TNF) in the treatment of ulcerative colitis (UC) patients in Germany will extend the prospective documentation of safety issu...

Real World Effectiveness of Ustekinumab in Induction and Maintenance Therapy for Crohn´s Disease

"RUN-CD" is an investigator initiated "Non interventional Trial" on biologics in Crohn´s Disease (CD) patients in Germany with a prospective documentation of effectiveness in induction an...

Companies [283 Associated Companies listed on BioPortfolio]

AbCellera Biologics, Inc.

AbCellera is a privately held company that develops next-generation monoclonal antibody therapies and provides enabling technologies to biotechnology and pharmaceutical partners. ...

AbCellera Biologics Inc.

AbCellera is a privately held company that engages in partnerships to discover and develop next-generation therapeutic antibodies. AbCellera’s single-cell platform integrates...

ABEC and WuXi Biologics

WuXi Biologics, a Hong Kong-listed company, is the only open-access biologics technology platform in the world offering end-to-end solutions to empower organizations to discover d...

Burst Biologics

Burst Biologics is a rapidly growing Biotechnology Company and federally registered tissue bank located in Boise, Idaho. Burst Biologics is a developer of effective tissue process...

MSD Biologics (UK) Limited

Avecia Biologics was acquired in February 2010 by MSD, the UK subsidiary of Merck & Co Inc, the world’s second largest pharmaceutical company. MSD Billingham is one of the world's leading contract ...

More Information about "AbCellera Biologics, Inc." on BioPortfolio

We have published hundreds of AbCellera Biologics, Inc. news stories on BioPortfolio along with dozens of AbCellera Biologics, Inc. Clinical Trials and PubMed Articles about AbCellera Biologics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of AbCellera Biologics, Inc. Companies in our database. You can also find out about relevant AbCellera Biologics, Inc. Drugs and Medications on this site too.

Quick Search

Relevant Topics

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Bioscience
Bioscience - any of the sciences that deal with living organisms.  The study of the nature, behavior, and uses of living organisms as applied to biology. Any of the branches of natural science dealing with living things, such as their structure, b...


Corporate Database Quicklinks



Searches Linking to this Company Record